• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

CDC advisers have recommend COVID-19 vaccines for children under 5. Final approval is expected later today

By
Erin Prater
Erin Prater
Down Arrow Button Icon
By
Erin Prater
Erin Prater
Down Arrow Button Icon
June 18, 2022, 1:53 PM ET

Advisers to the U.S. Centers for Disease Control and Prevention on Saturday unanimously recommended COVID vaccines for children under 5, the last group ineligible for the shots.

Final approval was expected later Saturday by CDC Director Dr. Rochelle Walensky, the Associated Press reported.

On Friday the U.S. Food and Drug administration approved emergency use of both Moderna and Pfizer vaccines for children ages 6 months through 4 years of age.

Shots are expected to become available as early as this coming week, with millions of doses already ordered for delivery to local providers. Around 18 million kids are eligible, but it’s uncertain how many will receive the vaccine. Children ages 5 through 11 become eligible in November, but less than a third of them have been vaccinated.

Pfizer’s vaccine for the youngest children uses a tenth of the adult dose, and three shots are needed—the first given two weeks apart, and the last around two months later, according to the AP.

Moderna’s vaccine for the same age group involves two shots—of a quarter of the adult dose—given four weeks apart. A third dose, at least a month after the second shot, is available to children who are immunocompromised.

It’s difficult to say how effective the shots will be, especially against emerging Omicron subvariants and potential future variants. Moderna’s course for ages 6 months through 4 years appeared to be about 40% effective at preventing milder disease during Omicron’s surge, the AP reported.

Pfizer said it’s three-dose series proved 80% effective. But data is limited, federal health officials point out, and reliable estimates aren’t yet available.

Sign up for the Coins2Day Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.
About the Author
By Erin Prater
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.